Copper sulphate veterinary grade API is supplied as copper(II) sulphate pentahydrate, CAS 7758-99-8, molecular formula CuSO₄·5H₂O, relative molecular mass 249.69 g/mol, and stoichiometric copper content 25.45% w/w. The unformatted substance occurs as blue crystalline particles or free-flowing blue powder after milling. Commercial API models are normally distinguished by particle-size control rather than chemical synthesis route: unmilled crystal, milled D₉₀ ≤ 150 µm, microfine D₉₀ ≤ 75 µm, and reduced-endotoxin injectable lots. Supplier-specific model codes may append abbreviations such as C for crystal, M for milled, and I for injectable; the chemical composition remains CuSO₄·5H₂O. The material is intended as the active substance in tablets, capsules, powders, granules, premix, injectable solutions, and oral solutions for veterinary medicine. Compendial release is based on the European Pharmacopoeia monograph for copper sulphate pentahydrate; identification is by reactions of copper and sulphate, assay is by iodometric titration, and impurity control uses atomic absorption spectrometry or inductively coupled plasma mass spectrometry. The product differs from feed-grade copper sulphate in the stringency of elemental impurity limits and GMP documentation, and from organic copper chelates in its immediate free-ion release and absence of organic ligand residues.

What Prevents Technical-Grade Copper Sulphate from Meeting Veterinary API Release Criteria?

Technical-grade copper sulphate from hydrometallurgical or synthetic sources carries variable lead, arsenic, cadmium, chloride, and acid-insoluble residues that are not controlled to compendial thresholds. A veterinary API release specification imposes separate limits for these impurities because copper ions are incorporated into products intended for long-term oral or parenteral administration to animals. In contrast to technical-grade material where arsenic may exceed 10 ppm and lead may exceed 30 ppm, the veterinary API grade typically reports lead ≤ 5 ppm, arsenic ≤ 3 ppm, iron ≤ 100 ppm, chloride ≤ 100 ppm, and water-insoluble matter ≤ 0.005%. The API is manufactured under ICH Q7 conditions for active pharmaceutical ingredients and is suitable for incorporation into veterinary medicinal products subject to current good manufacturing practice under 21 CFR 210/211. Feed-additive applications are additionally evaluated under Regulation (EC) No 1831/2003 and undesirable-substance limits of Directive 2002/32/EC. Therefore the distinction between technical, feed, and veterinary API grade is not assay alone; it is the controlled absence of toxicologically relevant impurities and the availability of batch-specific certificates of analysis.

The loss on drying value is not a drying loss of surface water; it corresponds mainly to the water of crystallization of the pentahydrate. Because the theoretical water content of CuSO₄·5H₂O is 36.07%, a loss on drying below 33.0% indicates partial dehydration to the lower hydrate or anhydrous form, which increases copper content per gram and can alter tablet hardness and aqueous solution pH. Storage in unlined paper sacks at ambient relative humidity above 60% may cause caking, whereas storage below 30% RH can promote slow efflorescence and hydrate loss at the crystal surface. The product is therefore re-tested for assay and water content after any exposure to uncontrolled humidity before use in batch calculations.

Tablet and capsule manufacture with copper sulphate pentahydrate is constrained by its brittleness, bulk density, and aqueous solubility rather than by drug load. Direct compression of microfine material is not generally feasible on high-speed rotary presses because the substance undergoes brittle fracture with limited plastic deformation; tablets exhibit capping at compression forces above 15 kN and weight variation from poor flow. Wet granulation in a 25 L high-shear granulator with aqueous povidone K30 solution, followed by fluid-bed drying at 50–60°C, produces granules with particle size 100–400 µm and acceptable compressibility for rotary press compression at 8–12 kN. For capsules, dosator-type filling machines achieve weight variation 2% RSD when the granule lubricant blend has a Hausner ratio below 1.25; powders with D₉₀ 75 µm may require forced feeding. Copper sulphate pentahydrate is freely soluble in water, so disintegration and dissolution are rapid once tablet or capsule matrix integrity is lost; dissolution testing for veterinary oral dosage forms is performed per Ph. Eur. 2.9.3 using 0.1 M hydrochloric acid or water as medium at 37°C. At drug loads below 5% w/w, dry blending in a bin blender requires geometric dilution because the dense copper particles segregate from lactose or microcrystalline cellulose; pre-blending with colloidal silicon dioxide at 0.5–1.0% w/w reduces segregation but does not replace granulation for very potent tablet strengths.

When Injectable Solutions Demand Low Endotoxin and Stabilized Copper Ion Activity

Injectable veterinary trace-mineral products use copper sulphate pentahydrate as a water-soluble source of divalent copper because it dissociates to Cu²⁺ and sulphate without organic ligand residues. Solutions are prepared in Water for Injections, adjusted to pH 3.5–4.5 with hydrochloric acid or sodium hydroxide, and protected from neutralization above pH 5.0 because copper hydroxide precipitation reduces filterability. In multielement injections containing zinc, manganese, or selenium, disodium EDTA or citric acid is added as a chelator to maintain soluble copper at pH up to 5.5; the chelator-to-copper molar ratio must be controlled because excess EDTA can sequester other trace elements and alter availability. Terminal sterilization is achieved at 121°C for 15 minutes, or sterile filtration is performed through a 0.22 µm PVDF or PES membrane before aseptic filling into Type I glass vials. Copper sulphate solutions must not be processed in aluminium equipment; 316L stainless steel, borosilicate glass, or polymer-lined transfer lines are used to avoid galvanic corrosion and metal-catalyzed oxidation of formulation components. Endotoxin testing follows Ph. Eur. 2.6.14, and sterility is confirmed by membrane filtration per Ph. Eur. 2.6.1. The API itself is not sterile; injectable lots are tested against a finished-product endotoxin limit derived from the intended dose, and material held at relative humidity above 60% is dried at 45°C before weighing to avoid hydrate-weight errors.

Copper sulphate pentahydrate is added to premixes and feed by direct blending or by spraying onto carrier particles. In a horizontal ribbon mixer at 60–70% fill and 30–40 rpm, the API is introduced after carrier preconditioning and mixed for 10–15 minutes; longer mixing can increase electrostatic dust formation and moisture uptake when ambient humidity exceeds 60%. The free cupric ion is catalytically active and accelerates oxidation of ascorbic acid, vitamin A, and unsaturated fats in mineral-vitamin premixes. Overages of 10–20% for vulnerable vitamins, addition of antioxidants such as ethoxyquin or BHT within regulatory limits, and moisture-barrier aluminium foil packaging are used to maintain vitamin activity. For granular oral solutions and soluble powders, copper sulphate is dissolved in the aqueous binder phase and sprayed onto sucrose or dextrose monohydrate in a fluid-bed coater; the spray rate is adjusted to obtain a target copper concentration of 100–250 mg/kg in the finished granule. Homogeneity of feed premixes is verified by collecting 10 thief samples and analyzing copper by a laboratory-validated inductively coupled plasma optical emission spectrometry method aligned to ISO 11885 after microwave-assisted acid digestion; a relative standard deviation below 5% is the usual release criterion for trace-mineral premixes. Because copper sulphate dissolves rapidly, it is preferred for oral rehydration and start-up water supplementation, but its pro-oxidant activity makes it less suitable than tribasic copper chloride for vitamin-sensitive feeds with prolonged storage at 25°C/60% RH.

Solubility, Hydrate Stability, and Vitamin Interaction Comparisons Across Copper Sources

Copper sulphate pentahydrate differs from copper carbonate, copper oxide, tribasic copper chloride, and organic chelates in water solubility and free-copper availability. Copper sulphate pentahydrate has water solubility above 200 g/L at 20°C, whereas copper carbonate and copper oxide are practically insoluble, and tribasic copper chloride has low solubility under neutral pH. This solubility difference makes copper sulphate the usual choice for injectable solutions and oral rehydration products, but it also means the salt releases free cupric ion immediately upon wetting, which accelerates oxidation of oxygen-sensitive nutrients. Copper carbonate and tribasic copper chloride are selected in some premixes because their lower water solubility reduces vitamin degradation and permits higher inclusion rates without caking. Organic chelates such as copper glycinate or copper lysine complexes have lower elemental copper content, generally 10–20% Cu, and are used where reduced antagonism with zinc or iron and slower release are required. Anhydrous copper sulphate contains 39.81% Cu by weight but is hygroscopic and must not be substituted on an equal-weight basis for the pentahydrate in wet granulation or aqueous solutions because hydration has a heat effect and changes volume. Comparisons based on copper content should therefore use the elemental-copper equivalent: 100 g of copper sulphate pentahydrate is equivalent to 25.45 g elemental Cu, while the same elemental quantity requires a different mass of oxide, carbonate, or chelate depending on assay.

The use of copper sulphate veterinary API in oral solutions requires pH adjustment to avoid precipitation; stock solutions are prepared in demineralized water at pH 3.5–4.5 and diluted before administration because copper salts are astringent and can irritate gastric mucosa at high concentration. In powders and granules for feed or drinking water, the API may be blended with citric acid or sodium citrate to buffer the solution and improve palatability; however, citrate at high concentration can reduce free cupric ion and should be accounted for in efficacy or bioequivalence studies. Formulators should not combine copper sulphate with strong reducing agents such as ascorbic acid in the same aqueous phase without chelation or antioxidant protection, because the resulting redox reaction can reduce copper to cuprous oxide. When switching from copper carbonate or tribasic copper chloride to copper sulphate pentahydrate in a premix formulation, the change must be calculated on elemental copper content and validated by copper recovery in the finished feed, because differences in hydration, assay, and matrix oxidation affect batch performance. Published data for high-load tablet and capsule configurations using copper sulphate as the sole active ingredient is limited; pilot studies using the intended granulation and drying parameters are required because hydrate loss during drying alters assay and tableting characteristics.